A—Major criteria | |
(a) exposure to an external stimulus prior to clinical manifestation (e.g. infection, vaccine, silicone, ...) | |
(b) typical clinical manifestations I. myalgia, myositis or muscle weakness II. arthralgia and/or arthritis III. chronic fatigue, sleep disturbances IV. neurological manifestations V. cognitive impairment VI. pyrexia, dry mouth | |
(c) removal of trigger induces improvement | |
B— Minor criteria | |
(a) autoantibodies or antibodies directed against the adjuvant | |
(b) specific HLA (e.g. HLA DRB1, HLA DQB1) | |
(c) evolvement of an autoimmune disease (e.g. SSc) |